Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MIRUM PHARMACEUTICALS, INC.

(MIRM)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Mirum Inks Japan License for Maralixibat With Takeda

09/21/2021 | 06:39am EDT

By Colin Kellaher

Mirum Pharmaceuticals Inc. on Tuesday said it signed an exclusive licensing agreement with Takeda Pharmaceutical Co. for maralixibat for rare pediatric liver diseases in Japan.

Mirum, a Foster City, Calif., biopharmaceutical company, said Takeda would be responsible for development, regulatory approval and commercialization of maralixibat in Japan for Alagille syndrome, progressive familial intrahepatic cholestasis and biliary atresia.

The U.S. Food and Drug Administration is currently reviewing Mirum's application for maralixibat to treat cholestatic pruritus, or itch, in patients with Alagille syndrome, with a target action date of Sept. 29.

Mirum, which earlier this month filed for European approval of maralixibat to treat cholestatic liver disease in patients with Alagille syndrome, said it is looking for partners outside the U.S. and Europe to expand the drug's global reach.

Write to Colin Kellaher at colin.kellaher@wsj.com

(END) Dow Jones Newswires

09-21-21 0839ET

Stocks mentioned in the article
ChangeLast1st jan.
MIRUM PHARMACEUTICALS, INC. -0.25% 15.75 Delayed Quote.-9.79%
TAKEDA PHARMACEUTICAL COMPANY LIMITED -1.20% 3207 End-of-day quote.-14.59%
All news about MIRUM PHARMACEUTICALS, INC.
09/30MIRUM PHARMACEUTICALS : HC Wainwright Raises Price Target for Mirum Pharmaceuticals to $64..
MT
09/30MIRUM PHARMACEUTICALS : Baird Adjusts Mirum Pharmaceuticals PT to $34 From $30, Maintains ..
MT
09/30MIRUM PHARMACEUTICALS : SVB Leerink Adjusts Price Target on Mirum Pharmaceuticals to $41 F..
MT
09/30MIRUM PHARMACEUTICALS : Raymond James Adjusts Mirum Pharmaceuticals PT to $69 from $51, Ma..
MT
09/29MIRUM PHARMACEUTICALS : U.S. FDA Approves LIVMARLI (maralixibat) as the First and Only App..
PU
09/29MIRUM PHARMACEUTICALS, INC. : Entry into a Material Definitive Agreement, Other Events, Fi..
AQ
09/29MIRUM PHARMACEUTICALS : Gets FDA's OK for Livmarli Oral Solution to Treat Chronic Itch in ..
MT
09/29MIRUM PHARMACEUTICALS : oral drug becomes first U.S. approved Alagille syndrome therapy
RE
09/29MIRUM PHARMACEUTICALS : FDA approves Mirum Pharma's drug for itching associated with rare ..
RE
09/29MIRUM PHARMACEUTICALS : U.S. FDA Approves LIVMARLI (maralixibat) as the First and Only App..
BU
More news
Analyst Recommendations on MIRUM PHARMACEUTICALS, INC.
More recommendations
Financials (USD)
Sales 2021 35,1 M - -
Net income 2021 -164 M - -
Net cash 2021 259 M - -
P/E ratio 2021 -2,91x
Yield 2021 -
Capitalization 478 M 478 M -
EV / Sales 2021 6,23x
EV / Sales 2022 4,25x
Nbr of Employees 120
Free-Float 90,5%
Chart MIRUM PHARMACEUTICALS, INC.
Duration : Period :
Mirum Pharmaceuticals, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends MIRUM PHARMACEUTICALS, INC.
Short TermMid-TermLong Term
TrendsBearishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 7
Last Close Price 15,75 $
Average target price 54,57 $
Spread / Average Target 246%
EPS Revisions
Managers and Directors
Christopher Peetz President, Chief Executive Officer & Director
Ian Clements Chief Financial Officer
Michael G. Grey Chairman
Pamela Vig Chief Scientific Officer
Edwin J. Tucker Chief Medical Officer
Sector and Competitors
1st jan.Capi. (M$)
MIRUM PHARMACEUTICALS, INC.-9.79%478
MODERNA, INC.225.04%137 066
LONZA GROUP AG32.03%60 786
IQVIA HOLDINGS INC.42.23%48 830
SEAGEN INC.-0.71%31 638
CELLTRION, INC.-39.42%25 233